HomeNewsBusinessThe fundraising tsunami few expected during COVID-19

The fundraising tsunami few expected during COVID-19

Moneycontrol spoke to corporate India’s top merchant bankers and capital market lawyers to decode the enormous wave of fundraising in the equity capital markets during the lockdown, the key triggers and trends and the road ahead…

June 12, 2020 / 12:21 IST
Story continues below Advertisement

 “Only when the tide goes out, do you discover who has been swimming naked.”

These words from the Oracle of Omaha and legendary investor Warren Buffet serve as the ideal reality check for investors and corporates today.

Story continues below Advertisement

They are grappling with the triumvirate of an unstable economic environment, pessimistic growth projections and volatile stock markets. They have traded a global economic crisis in the past but how do they trade a global healthcare crisis? There is no model, no worst-case scenario and the trillion-dollar question on everyone’s lips is – is there a vaccine at the end of this long, dark tunnel?

When uncertainty reigns, cash is king. And on cue, the Indian equity capital markets have witnessed frenetic, back-to-back fundraising by domestic corporates in the ‘COVID -19 quarter’.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show